Business Relations Table

Beispiel: brt.php?search=wide&s=wide&p=adjective&o=wideness

BR-Relations: 187

From Domain	Role	To Domain	Path
ipharminc.com	>>isreferencefrom.png CID: 0	intelligencejournal.com	/innovation-pharma-obtains-fda-guidance-for-brilacidin-phase-3-program
ipharminc.com	>>isreferencefrom.png CID: 0	biosectrx.com	/post/companies-curing-covid-19
ipharminc.com	>>isreferencefrom.png CID: 0	marketnewsdesk.com	/index.php/page/42247/
ipharminc.com	>>isreferencefrom.png CID: 0	studyscavenger.com	/innovation-pharmaceuticals-phase-1-trial-of-brilacidin-for-ulcerative-colitis-meets-primary-endpoints-positive-topline-results-of-oral-brilacidin/
ipharminc.com	>>isreferencefrom.png CID: 0	cellceutix.com	brilacidin-1/
ipharminc.com	>>isreferencefrom.png CID: 0	pt.alfasigma.com	/produtos/brilacidin-acordo-de-licenciamento-com-a-innovation-pharmaceuticals/
ipharminc.com	>>isreferencefrom.png CID: 0	healthcare.levinassociates.com	/2019/07/26/health-care-ma-deals-week-ending-july-26-2019/
ipharminc.com	>>isreferencefrom.png CID: 0	distrilist.eu	/most-innovative-pharmaceutical-companies-in-usa-691-listed/
ipharminc.com	>>isreferencefrom.png CID: 0	ibi.gmu.edu	/news-archive/page/30/
ipharminc.com	>>isreferencefrom.png CID: 0	microbiometimes.com	/the-microbiome-drug-landscape-report-promising-clinical-performance-and-signs-of-a-maturing-industry-4/
ipharminc.com	>>isreferencefrom.png CID: 0	biopharmajournal.com	/2020/01/22/clinical-trial-of-experimental-ulcerative-colitis-drug-humming-along/
ipharminc.com	>>isreferencefrom.png CID: 0	aviseanalytics.com	/top-5-companies-exploring-potential-of-gene-expression-and-pathway-signalling-in-the-ovarian-cancer-therapeutic-space/
ipharminc.com	>>isreferencefrom.png CID: 0	pharmaceuticalprocessingworld.com	/innovation-pharmaceuticals-signs-drug-product-manufacturing-contract-with-corerx/
ipharminc.com	>>isreferencefrom.png CID: 0	openlongevity.org	/covid19_drugs
jamanetwork.com	>>isreferencefrom.png CID: 0	ipharminc.com	/press-release/2019/4/23/innovation-pharmaceuticals-jama-article-reinforces-need-for-novel-oral-mucositis-treatments-in-supportive-cancer-care
worldibdday.org	>>isreferencefrom.png CID: 0	ipharminc.com	/press-release/2019/5/16/innovation-pharmaceuticals-announces-non-binding-term-sheet-signed-with-global-pharmaceutical-company-to-develop-and-commercialize-brilacidin-for-ulcerative-proctitisproctosigmoiditis
abstracts.asco.org	>>isreferencefrom.png CID: 0	ipharminc.com	/new-blog/2018/9/24/brilacidin-for-oral-mucositis-at-a-glance-comparative-data-presentation-with-other-investigational-om-drugs
marketwired.com	>>isreferencefrom.png CID: 0	ipharminc.com	/press-release/2016/11/16/cellceutix-announces-positive-top-line-data-from-phase-2b-absssi-trial-single-dose-brilacidin-comparable-to-7-days-of-daptomycin
bit.ly	>>isreferencefrom.png CID: 0	ipharminc.com	/press-release/2017/4/8/cellceutix-ceo-discusses-brilacidin-following-interim-trial-results-exceeding-expectations-for-treating-oral-mucositis-and-inflammatory-bowel-disease
ir.valeant.com	>>isreferencefrom.png CID: 0	ipharminc.com	/new-blog/2017/7/13/ulcerative-proctitisulcerative-proctosigmoiditissubstantial-opportunity-exists-for-newer-therapies-like-brilacidin-to-emerge

1 2 3 ... 10 Nächste

Business Relations Table - o4.fyi ()

BR-Editor

Domain-Statistiken für "ipharminc.com"

BR-Relations: 187